Daiichi Sankyo Press Release

10/09/2018 - 01:22 Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Announce Second Public Recruitment Offering of "JOINUS", a Joint Research Program to Discover New Drugs using Drug-Repositioning Compound Library
10/02/2018 - 23:33 Japan MHLW Grants Orphan Drug Designation to Axicabtagene Ciloleucel for Treatment of Certain Types of B-Cell Lymphoma
09/11/2018 - 19:19 Daiichi Sankyos FLT3 Inhibitor Quizartinib Receives Orphan Drug Designation from Japanese MHLW for FLT3-Mutated AML
08/07/2018 - 07:11 Daiichi Sankyo Announces Change in Principal Shareholders
08/01/2018 - 06:27 FDA Grants Breakthrough Therapy Designation to Daiichi Sankyos FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML
07/31/2018 - 08:59 Daiichi Sankyo Announces Split off (Simple Absorption-type Split) and Transfer of 41 Long-listed Products in Japan
07/31/2018 - 07:10 Daiichi Sankyo Announces Reversal of Tax-related Expenses in its Non-consolidated Financial Results (Japanese GAAP)
07/30/2018 - 18:03 Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
07/02/2018 - 18:04 Daiichi Sankyo Obtains Approval for Additional Indication and Dosage for Diagnogreen for Injection 25 mg in Japan
06/14/2018 - 23:09 Daiichi Sankyo Launches FENTANYL CITRATE TAPE for 1day DAIICHI SANKYO in Japan for Long-Acting Cancer Pain Relief
05/31/2018 - 13:03 Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with Advanced HER2-Overexpressing or HER2-Mutated Non-Squamous Non-Small Cell Lung Cancer
05/30/2018 - 13:18 Daiichi Sankyo U.S. subsidiary, Luitpold Pharmaceuticals, Inc., to Be Merged with Its Own Subsidiaries and Renamed
05/30/2018 - 12:50 Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development
05/15/2018 - 18:25 Daiichi Sankyo Launches Naruvein Injection for Cancer Pain Treatment in Japan
05/14/2018 - 20:25 Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
05/10/2018 - 22:44 Daiichi Sankyo Announces Changes to Representative Directors and Members of the Audit and Supervisory Board
04/27/2018 - 00:43 Daiichi Sankyo to Reorganize Kitasato Daiichi Sankyo Vaccine into Specialized Manufacturing Subsidiary
04/25/2018 - 01:43 Daiichi Sankyo Announces Phase 1/2 Clinical Trial Results for DS-5141 (Therapeutic Agent for Duchenne Muscular Dystrophy) in Japan
04/17/2018 - 21:37 AstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium 10 mg and 20 mg Granules for Suspension, Sachet, in Japan
04/04/2018 - 22:27 Daiichi Sankyo and DarwinHealth Enter Exclusive Research Collaboration for Novel Cancer Target Initiative
03/30/2018 - 01:57 Daiichi Sankyo Agrees to Modify the Terms of the Settlement Program for U.S. Olmesartan Products Liability Litigation
03/27/2018 - 00:22 Daiichi Sankyos HER2-Targeting Antibody Drug Conjugate DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan MHLW
03/07/2018 - 21:01 Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with HER2-Expressing Advanced Colorectal Cancer
02/26/2018 - 19:54 Daiichi Sankyo Announces NDA submission in Japan of Esaxerenone for Treatment of Hypertension
02/26/2018 - 18:48 Daiichi Sankyo Reports Rupture of Liquid Storage Tank at Kitamoto Facility of Kitasato Daiichi Sankyo Vaccine
02/22/2018 - 21:07 Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer
02/22/2018 - 19:36 Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2018
02/22/2018 - 01:15 Daiichi Sankyo Submits Application for Additional Indication and Dosage for Diagnogreen for Injection 25 mg in Japan
02/15/2018 - 02:23 Daiichi Sankyo Submits Marketing Application for Mirogabalin in Japan
02/06/2018 - 18:48 Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
02/01/2018 - 22:09 Daiichi Sankyo Selected for Silver Class of RobecoSAM Sustainability Award 2018
02/01/2018 - 22:08 Daiichi Sankyo Announces Update on Amgen Inc.s Phase 3 Clinical Trial Evaluating Denosumab as Adjuvant Breast Cancer Treatment
01/19/2018 - 03:52 Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer at ASCO 2018 Gastrointestinal Cancers Symposium
12/14/2017 - 03:57 Winners of 10th Manpei Suzuki International Prize for Diabetes Research and 11th Manpei Suzuki Prize for Diabetes Care and Education Announced
12/12/2017 - 21:49 Once-Daily, Oral LIXIANA (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study
12/12/2017 - 19:06 Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
12/07/2017 - 19:35 Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Breast Cancer at San Antonio Breast Cancer Symposium
12/06/2017 - 22:54 Daiichi Sankyos Subsidiary Daiichi Sankyo Espha to Launch New Generic Drugs
11/30/2017 - 21:39 Daiichi Sankyo and Translational Sciences Conclude Agreement, after Successful Phase 1a Trial, as Part of Daiichi Sankyo Portfolio Prioritization
11/30/2017 - 00:33 Daiichi Sankyo to Absorb Japan Research Subsidiary, Asubio Pharma Co., Ltd.
11/29/2017 - 22:07 Daiichi Sankyo to Convert Kitasato Daiichi Sankyo Vaccine into Wholly Owned Subsidiary
11/28/2017 - 23:11 Daiichi Sankyo Launches Anticoagulant Lixiana OD Tablets (orally disintegrating tablets) in Japan
11/20/2017 - 23:44 Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Advanced Gastric Cancer
11/14/2017 - 20:46 New LIXIANA sub-analysis from the ENGAGE AF-TIMI 48 trial presented at the American Heart Association Annual Scientific Sessions 2017
10/30/2017 - 00:18 Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing
10/15/2017 - 23:34 Commencement of Collaborative Research on Measurement of Exosomes in Blood from Cancer Patients
10/10/2017 - 19:18 Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct JOINUS, a New Drug Discovery Program Using Drug-Repositioning Compound Library
09/29/2017 - 04:17 Daiichi Sankyo Underwrites All Shares Issued by Kitasato Daiichi Sankyo Vaccine
09/25/2017 - 18:21 Daiichi Sankyo Announces TaNeDS Global 2018 Collaborative Drug Discovery Program
09/24/2017 - 20:15 Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Study in Japan of Esaxerenone for Treatment of Essential Hypertension
09/14/2017 - 19:37 Daiichi Sankyo Listed on the Dow Jones Sustainability Indices World Index
09/14/2017 - 18:14 MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myeloid Leukemia Therapies
09/11/2017 - 18:51 Daiichi Sankyo Presents New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors at European Society for Medical Oncology (ESMO) 2017 Congress
09/06/2017 - 21:06 Sanford Burnham Prebys and Daiichi Sankyo Announce Enrollment of First Subject in a Phase 1 Clinical Trial of DS-1211 in Healthy Volunteers
09/06/2017 - 20:40 Japans First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug Launch of CANALIA Combination Tablets, a type 2 diabetes mellitus treatment agent
08/31/2017 - 22:44 Restriction on prescription period lifted for antiepileptic VIMPAT Tablets 50 mg and 100 mg
08/31/2017 - 02:27 Daiichi Sankyo Terminates Development and Commercialization Agreement with Charleston Laboratories Regarding Hydrocodone Products in the U.S., including CL-108
08/31/2017 - 01:22 Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabalin in Diabetic Peripheral Neuropathic Pain
08/29/2017 - 21:56 Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Metastatic Breast Cancer
08/29/2017 - 20:01 FDA Grants Breakthrough Therapy Designation to Daiichi Sankyos DS-8201 for HER2-Positive Metastatic Breast Cancer
08/28/2017 - 18:40 Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitorfor Solid Tumors
08/28/2017 - 03:51 Daiichi Sankyo Announces New Oxycodone Tablets "Daiichi Sankyo" for Cancer Pain Treatment in Japan
08/25/2017 - 03:30 Antiepileptic VIMPAT Tablets 50 mg and 100 mg approved for monotherapy for Partial-onset Seizures in Epilepsy Patients
08/25/2017 - 01:38 Daiichi Sankyo Obtains Approval in Japan for Additional Indication and Dosage for Ovisot for Injection in Diagnosis of Vasospastic Angina
08/06/2017 - 21:06 Daiichi Sankyo to Collaborate on Commercialization of Generic Transdermal Fentanyl Citrate Patches for Long-Acting Cancer Pain Relief
08/06/2017 - 19:39 Daiichi Sankyo Invests in Osaka University Spin-Off Venture with the Aim of Commercializing iPS-derived Cardiomyocyte Sheet
08/01/2017 - 16:40 Daiichi Sankyo Announces Settlement Agreement on U.S. Products Liability Litigation
07/19/2017 - 18:43 Daiichi Sankyo Opens Applications for Investigator-Initiated Studies Program
07/18/2017 - 19:11 Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody Collaboration
07/18/2017 - 02:38 Daiichi Sankyo Announces Completion of Payment Concerning Disposal of Treasury Shares as Restricted Share-Based Remuneration
07/11/2017 - 19:18 Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration
07/10/2017 - 21:07 Oncolytic Virus G47 (DS-1647) designated as Orphan Drug under Orphan Drug/Medical Device Designation System
07/10/2017 - 20:36 Daiichi Sankyo Selected for Ninth Consecutive Year as Constituent of FTSE4Good Global Index by FTSE Russell
07/02/2017 - 21:31 Daiichi Sankyo Obtains Approval for Additional Indication for PRALIA Subcutaneous Injection 60mg Syringe
07/02/2017 - 20:39 Japans First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug Application approved in Japan for CANALIA Combination Tablets, a type 2 diabetes mellitus treatment agent
06/29/2017 - 21:28 Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes
06/18/2017 - 20:41 Daiichi Sankyo Announces Disposal of Treasury Shares as Restricted Share-Based Remuneration
06/18/2017 - 19:22 Daiichi Sankyo Announces Launch of Narurapid Tablets and Narusus Tablets for Cancer Pain Treatment
06/05/2017 - 19:22 New Precision Medicine Data on DS-8201 in HER2-Expressing Breast Cancer Revealed at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
05/10/2017 - 23:44 Representative: Sunao Manabe, Representative Director, President and COO
05/10/2017 - 22:26 Differences Between Consolidated Results for Fiscal 2016 and Fiscal 2015
04/28/2017 - 04:39 Daiichi Sankyo Revises Fiscal 2016 Consolidated Forecasts and Announces Fiscal 2017 Consolidated Forecasts
04/28/2017 - 04:26 Daiichi Sankyo Announces the Introduction of a Restricted Share-Based Remuneration Plan
04/28/2017 - 01:57 Daiichi Sankyo Announces Impairment Loss Related to Kitasato Daiichi Sankyo Vaccine
04/26/2017 - 23:24 Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio
04/21/2017 - 19:16 Daiichi Sankyo Initiates Pivotal Phase 3 study in Japan of Esaxerenone in Patients with Diabetic Nephropathy
04/03/2017 - 22:38 Daiichi Sankyo, Inc. Announces Sale of Pharmaceutical Packaging Plant in Bethlehem, PA
03/30/2017 - 21:46 Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily Lixiana (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation
03/30/2017 - 00:52 Daiichi Sankyo Announces Manufacture and Sales Approval in Japan of Narurapid Tablets and Narusus Tablets for Cancer Pain Treatment
03/30/2017 - 00:35 Daiichi Sankyo Submits Application for Additional Indication and Dosage for Ovisot Intracoronary Injection 0.1g in Diagnosis of Vasospastic Angina
03/22/2017 - 23:28 Daiichi Sankyo to Facilitate New Drug Discovery in 2017 through Collaborative Research and Grants
03/15/2017 - 22:50 National Institutes of Biomedical Innovation, Health and Nutrition
03/13/2017 - 01:06 Daiichi Sankyo Announces Large-scale Registry of Venous Thromboembolism (VTE) in Cancer Patients
03/13/2017 - 00:40 Daiichi Sankyo Enters Agreement with Heptares Therapeutics to Discover and Develop Novel, Small-Molecules for the Treatment of Pain
03/08/2017 - 01:14 Daiichi Sankyo Announces New Oxycodone Extended Release Tablets "Daiichi Sankyo" for Sustained Cancer Pain Treatment
02/21/2017 - 23:04 Daiichi Sankyo Joins IkuBoss Alliance
02/14/2017 - 22:37 Daiichi Sankyo Strengthens Authorized Generic Business through Daiichi Sankyo Espha
02/03/2017 - 20:18 Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Receive Complete Response Letter from FDA for New Drug Application for CL-108 (hydrocodone, acetaminophen, promethazine) Tablets for Oral Use
01/30/2017 - 23:35 Daiichi Sankyo Announces New Chairman and President
01/18/2017 - 19:27 Daiichi Sankyo Initiates Phase 1/2 Study of Novel Antibody Drug Conjugate U3-1402 in Patients with HER3-Positive Metastatic or Unresectable Breast Cancer
Copy and paste this code to display this page on your website .
Syndicate content